CMS certification 224007
McLean Hospital Corporation
115 Mill Street, Belmont, MA 02478
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
Clinicians registered at this address
551 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 54 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Clinical | 284 |
| Psychiatry | 120 |
| Psychiatric/Mental Health | 20 |
| Mental Health | 16 |
| Psychologist | 15 |
| Social Worker | 14 |
| Clinical Nurse Specialist | 10 |
| Child & Adolescent Psychiatry | 7 |
| Clinical Neuropsychologist | 7 |
| Internal Medicine | 6 |
| Nurse Practitioner | 6 |
| Addiction Psychiatry | 5 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $951,289
- 2020 $1.3M
- 2021 $1.1M
- 2022 $629,573
- 2023 $536,168
- 2024 $243,096
- 2025 $115,660
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $56,160 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $56,160 | 1 |
| Eisai Inc. | $29,344 | 8 |
| E.R. Squibb & Sons, L.L.C. | $14,866 | 2 |
| Biogen, Inc. | $14,237 | 2 |
| Eli Lilly and Company | $1,053 | 1 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Su… Eisai Inc. | $29,344 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psych… E.R. Squibb & Sons, L.L.C. · NCT05980949 | $14,450 |
| Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Adu… Biogen, Inc. | $9,237 |
| A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) i… Biogen, Inc. | $5,000 |
| A PHASE 2 MULTICENTER, DOUBLE-BLIND, PARALLEL-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ADJUNCTIVE TREATMENT WITH BRENIPATIDE IN ADULT PART… Eli Lilly and Company · NCT07410507 | $1,053 |
| Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies E.R. Squibb & Sons, L.L.C. · NCT06585787 | $416 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
Common questions about McLean Hospital
Does McLean Hospital have an emergency room?
No. CMS does not list emergency services at McLean Hospital.
Does McLean Hospital receive money from drug and device companies?
Drug and device makers reported $115,660 in payments to McLean Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.